Arbutus to Participate in Virtual Fireside Chat at Chardan’s 4th Annual Genetic Medicines Conference
September 28 2020 - 8:00AM
Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage
biopharmaceutical company primarily focused on developing a cure
for people with chronic hepatitis B virus (HBV) infection as well
as therapies to treat coronaviruses (including COVID-19), today
announced that the Company will participate in a virtual fireside
chat at Chardan’s 4th Annual Genetic Medicines Conference on
Monday, October 5, 2020 at 1:00 pm ET.
Arbutus Fireside Chat Presenters:
William Collier, President and CEO; Dr. Michael
Sofia, Chief Scientific Officer; Dr. Gaston Picchio, Chief
Development Officer; and David Hastings, Chief Financial
Officer.
A live webcast of the virtual fireside chat can
be accessed through the Investors section of Arbutus’ website at
www.arbutusbio.com or directly at Live Webcast. An archived replay
of the webcast will be available on the Company’s website after the
conference.
About Arbutus
Arbutus Biopharma Corporation is a publicly
traded (Nasdaq: ABUS) biopharmaceutical company dedicated to
discovering, developing and commercializing a cure for people with
chronic hepatitis B virus (HBV) infection. The Company is advancing
multiple drug product candidates that may be combined into a
potentially curative regimen for chronic HBV infection. Arbutus has
also initiated a drug discovery and development effort for treating
coronaviruses (including COVID-19). For more information, visit
www.arbutusbio.com.
Contact Information
Investors and Media
William H. CollierPresident and CEO Phone: 267-469-0914Email:
ir@arbutusbio.comPam MurphyInvestor Relations ConsultantPhone:
267-469-0914Email: ir@arbutusbio.com
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From Apr 2023 to Apr 2024